|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
No significant correlation was found between expression of VEGF<sub>165</sub>b and VEGFR2 in tumours and non-tumor surgical margins.
|
29926253 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Areas covered</b>: Areas covered in this review include the molecular pathways of angiogenesis in glioblastoma, specifically the overexpression of vascular endothelial growth factor (VEGF) and robust formation of tumor neovasculature.
|
31356114 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumor conditioned media (TCMs) from both cell lines treated with PTHrP increases the number of cells, the migration and the tube formation in the endothelial HMEC-1 cells, whereas the neutralizing antibody against VEGF diminished this response.
|
30639585 |
2019 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Moreover, LINC00628 exerted its tumor suppressive function by repressing the vascular endothelial growth factor A (VEGFA) promoter activity.
|
30740671 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Overexpression of MMP-2 is found to facilitate tumour propagation through the involvement of vascular endothelial growth factor (VEGF).
|
31012354 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The results showed that VEGF can impair the migration capacity and immune function of mDCs through the RhoA-cofilin1 pathway mediated by the VEGF receptor 2, suggesting impaired motility of mDCs by VEGF is one of the aspects of immune escape mechanisms of tumors.
|
31169331 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Also, the expression levels of vascular endothelial growth factor (VEGF) and cysteine aspartyl-specific protease-7 (caspase-7) in tumor and liver tissues of mice bearing EAC tumor were determined.
|
31514445 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The results showed that, under the hypoxia condition induced by CoCl2, sorafenib pretreatment combined with intragastric administration of sorafenib more obviously suppressed tumor growth and decreased VEGF expression and MVD compared to sorafenib pretreatment alone, and induced cell apoptosis as well.
|
28592123 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The relationship between epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) pathways in tumor growth is well established.
|
31717527 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Jzu 17 suppressed VEGF-A-induced microvessel sprouting ex vivo and attenuated VEGF-A- or tumour cell-induced neovascularization in vivo.
|
31368127 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
TNBC patients have significantly higher expression of vascular endothelial growth factor (VEGF) in tumors compared to non-TNBC patients.
|
31285776 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
As VEGF mRNA is an endothelial cell-specific mitogen and a key regulator of angiogenesis in a variety of physiological and pathological processes, high expression levels of VEGF messenger RNA (mRNA) contribute to VEGF-driven angiogenesis in the hypoxic areas of solid tumors and then disrupt the vascular barrier, which may potentiate tumor cell extravasation.
|
31560359 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In ovo, PDA6606 cells and conditioned media polarized macrophages to the M2 phenotype, which in turn promoted tumour growth and angiogenesis via their surface marker profiles and VEGF production.
|
31177125 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of MIR31HG in vivo also promoted tumor growth via inhibition of miR-361 signals and elevated the expression of VEGF, FOXM1 and Twist for tumor growth.
|
31564967 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The MLT and ADR treatments also significantly decreased the Ki-67 protein and vascular endothelial growth factor (VEGF) expression levels in the tumour masses.
|
31066091 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data suggest that PD-1 and PD-L1 expression by TIIC in the tumor microenvironment is involved in treatment resistance, and that sequential therapy with immune checkpoint inhibitors could be a promising therapeutic strategy for ccRCC resistant to VEGF-TKI treatment.
|
30972888 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, VEGF-induced corneal angiogenesis and tumor development were significantly inhibited in mice lacking Akt1.
|
30984553 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition.
|
31501519 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The TF/factor VIIa complex enhances tumor growth by activating protease-activated receptor 2 signaling and by increasing the expression of angiogenic factors, such as vascular endothelial growth factor.
|
31096306 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The VEGFA levels in tumor supernatant were measured by ELISA.
|
30755242 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
First, upon the arrival of TDPAD/PLL-RT/pDNA [abbreviated as T(PD)] at the tumor site by the EPR effect, TDPAD reacts with excess H<sub>2</sub>O<sub>2</sub> in tumor tissue, contributing to the detachment of TDPAD, and PLL-RT then mediates the enhanced endocytosis of pDNA encoding shVEGF and significantly downregulates the expression of vascular endothelial growth factor (VEGF) in tumor tissue, exhibiting an outstanding antitumor effect.
|
31773940 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data further reinforced the importance of the AKT/MMP-2/VEGF loop in regulating anti-bFGF-induced tumour cell invasion and suggested the limitations of the bFGF-targeting strategy in lung cancer treatment.
|
31314153 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Pegaptanib might be a promising anti-tumour drug targeting VEGF to inhibit tumour vascular endothelial cell proliferation.
|
31364793 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Human hepatocellular carcinoma (HCC) is a VEGF-driven tumor often associated with chronic hepatitis B or C virus infection.
|
30439360 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Sunitinib treatment impaired RT2 tumour angiogenesis and growth, while overexpression of the vascular endothelial growth factor (VEGF)-B increased tumour angiogenesis though tumour growth was impaired.
|
31601958 |
2019 |